The FDA states there is limited available data regarding the effects of Cosentyx (secukinumab) on pregnancy, and therefore, it is difficult to determine any drug-associated adverse developmental effects. For this reason, it is critical to consult with your doctor before taking Cosentyx if you are pregnant, think you are pregnant or plan to become pregnant.
Cosentyx, Labor and Delivery
The effects of Cosentyx on human labor and delivery are unknown. In regards to “major” birth defects, the FDA states the background risk in the U.S. general population is 2%-4% and 15%-20% for miscarriages in “clinically recognized pregnancies.”
Cosentyx and Lactation
The FDA states it is unknown whether or not Cosentyx is excreted in human milk, nor is it known whether or not Cosentyx consumption affects breast milk production or affects breast-fed children.
The FDA states that any underlying health conditions of the mother, the mother’s need for Cosentyx, and potential health benefits of breastfeeding the baby or babies should be considered before administering Cosentyx to a breastfeeding mother.
Cosentyx and Fertility
The FDA states that animal studies have not been conducted to determine the carcinogenic and/or mutagenic effects Cosentyx could have on fertility. Further, the FDA states that no effects on fertility were observed in mice that were administered a murine analog of secukinumab at doses up to 150mg/kg once per week both before and during mating.